GARDP commits $20 million for Bugworks’ molecule to fight MDR bacteria
Swiss not-for-profit organisation Global Antibiotic Research & Development Partnership (GARDP) will provide up to $20 million in technical and financial support for an innovative compound with broad-spectrum antibiotic activity biopharma firm Bugworks Research Inc. is developing against multidrug-resistant bacteria that cause life-threatening infections. Also read: Sustained rise in antimicrobial resistance in India: ICMR study The … Read more
